VIMOVO 500 mg/20 mg modified-release tablets

  • Name:

    VIMOVO 500 mg/20 mg modified-release tablets

  • Company:
    info
  • Active Ingredients:

    Esomeprazole magnesium trihydrate, Naproxen

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 30/10/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 4/3/2019

Click on this link to Download PDF directly

AstraZeneca Pharmaceuticals (Ireland) DAC

AstraZeneca Pharmaceuticals (Ireland) DAC

Company Products

Medicine NameActive Ingredients
Medicine Name Alvesco 160 micrograms pressurised inhalation,solution Active Ingredients Ciclesonide
Medicine Name Alvesco 80 micrograms pressurised inhalation,solution Active Ingredients Ciclesonide
Medicine Name Arimidex Active Ingredients Anastrozole
Medicine Name Atacand 8mg 16mg Tablets Active Ingredients Candesartan Cilexetil
Medicine Name Atacand Plus 16/12.5mg Active Ingredients Candesartan Cilexetil, Hydrochlorothiazide
Medicine Name Bricanyl Turbohaler Active Ingredients Terbutaline sulfate
Medicine Name Brilique 60 mg film-coated tablets Active Ingredients Ticagrelor
Medicine Name Brilique 90 mg film coated tablets Active Ingredients Ticagrelor
Medicine Name Brilique 90 mg Orodispersible Tablets Active Ingredients Ticagrelor
Medicine Name Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen Active Ingredients Exenatide
Medicine Name Byetta 5 micrograms solution for injection, prefilled pen. Byetta 10 micrograms solution for injection, prefilled pen Active Ingredients Exenatide
Medicine Name Casodex 50mg Tablets Active Ingredients Bicalutamide
Medicine Name Crestor 5 mg, 10 mg, 20 mg and 40 mg Tablets Active Ingredients Rosuvastatin Calcium
Medicine Name Daxas 250 mcg Film-Coated Tablets Active Ingredients roflumilast
Medicine Name Daxas 500 mcg Film-coated Tablets Active Ingredients roflumilast
Medicine Name Fasenra 30 mg solution for injection in pre filled syringe Active Ingredients Benralizumab
Medicine Name Faslodex Active Ingredients Fulvestrant
Medicine Name Forxiga 10 mg Film coated tablets Active Ingredients Dapagliflozin propanediol monohydrate
Medicine Name Forxiga 5 mg film coated tablets Active Ingredients Dapagliflozin propanediol monohydrate
Medicine Name IMFINZI 50 mg/mL concentrate for solution for infusion Active Ingredients durvalumab
Medicine Name IRESSA 250 mg film-coated tablets Active Ingredients gefitinib
Medicine Name Komboglyze 2.5mg-1000mg Tablets Active Ingredients Metformin Hydrochloride, Saxagliptin hydrochloride
Medicine Name Komboglyze 2.5mg-850mg Tablets Active Ingredients Metformin Hydrochloride, Saxagliptin hydrochloride
Medicine Name Losec MUPS 10mg Gastro-resistant Tablets Active Ingredients omeprazole magnesium
Medicine Name Losec MUPS 20mg Gastro-resistant Tablets Active Ingredients omeprazole magnesium
1 - 0 of 56 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 30 October 2019 PIL

Reasons for updating

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 4 March 2019 PIL

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 4 March 2019 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 16 May 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 16 May 2017 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.2 – Updated subheading from ‘older people’ to ‘elderly’ in line with QRD template.
Section 4.4 – Updated subheading from ‘older people’ to ‘elderly’ in line with QRD template.
Section 4.8 – Addition of ‘fundic gland polyps (benign)’ to ADR table for Esomeprazole under the Gastrointestinal SOC with frequency of ‘common’
Section 5.2 – Updated subheading from ‘older people’ to ‘elderly’ in line with QRD template.
Section 10 – Date of revision of text updated.

Updated on 15 May 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 15 May 2017 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 22 March 2017 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.1 - List of excipients
  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 2 – Updated information relating to excipients with known effect
Section 3 – Updated information relating to pharmaceutical form
Section 4.2 – Updated information in line with QRD template
Section 4.3 – Minor editorial changes and correct of spelling for Child Pugh C.
Section 4.4 – Updated spelling of esomeprazole and dyspepsia. Updated heading in line with QRD.
Section 4.8 – Minor formatting changes to ADR table, corrected spelling of erythematosus and pruritis and addition of reference to section 4.4. Update of HPRA contact details.
Section 5.1 –Minor formatting changes.
Section 6.1 – Updated list of excipients with additional information for hypromellose and methacrylic acid-ethyl acrylate copolymer.
Section 9 – Updated renewal date
Section 10 – Updated date of revision of text

Updated on 22 March 2017 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.1 - List of excipients
  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 1 – Removal of black triangle
Section 2 – Updated information relating to excipients with known effect
Section 3 – Updated information relating to pharmaceutical form
Section 4.2 – Updated information in line with QRD template
Section 4.4 – Updated spelling of esomeprazole and dyspepsia. Updated heading in line with QRD. Addition of information relating to the interaction between Chromogranin A with investigations for neuroendocrine tumours.
Section 4.8 – Minor formatting changes to ADR table, corrected spelling of erythematosus and pruritis and addition of reference to section 4.4. Update of HPRA contact details.
Section 5.1 – Updated information relating to the interaction between Chromogranin A with investigations for neuroendocrine tumours and minor formatting changes.
Section 6.1 – Updated list of excipients with additional information for hypromellose and methacrylic acid-ethyl acrylate copolymer.
Section 9 – Updated renewal date
Section 10 – Updated date of revision of text

Updated on 21 March 2017 PIL

Reasons for updating

  • Change to section 3 - how to take/use
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 5 - how to store or dispose
  • Change to section 6 - what the product contains
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision
  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - warnings and precautions

Updated on 27 January 2017 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4 – Updated with information relating to interaction between Chromogranin A level with investigations for neuroendocrine tumours.

Section 5.1 – Updated information on effects related to acid inhibition.

Section 10 – Updated date of revision of text.

Updated on 26 January 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Updated on 1 February 2016 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4: Addition of Dermatological effect for esomeprazole.

Section 4.8: Addition of new AE for Skin and subcutaneous tissue disorders.

Section 10: Date of revision.

Updated on 29 January 2016 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
  • Change to improve clarity and readability

Updated on 4 March 2014 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.8 addition of hypokalaemia to SE

Section 10 date of revision

Updated on 18 October 2013 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

·         Section 2 - administrative changes

·         Section 4.1 – administrative changes

·         Section 4.2 – administrative changes and more detail on use in paediatric population

·         Section 4.3 – administrative changes

·         Section 4.4 - administrative changes and updated to align with the CDS wording with regards to combination use of Vimovo with non-aspirin NSAIDs. Information on angiotensin II receptor antagonists has been added in the subsection on renal effects. The subsection on impaired renal function has been updated to include angiotensin II receptor antagonists and ACE inhibitors. There has also been an update regarding interaction with clopidogrel.

·         Section 4.5 - updated with regards to potential interaction with tacrolimus and information on tacrolimus and cyclosporin has been split into separate subsections. There has been an update with regards to information on the combination of NSAIDs and angiotensin II receptor antagonists and ACEinhibitors. The text concerning potential interaction with methotrexate has been updated and there is an update to the information on interaction with clopidogrel.

·         Section 4.6 - updated with regards to female infertility and spontaneous abortion.

·         Section 4.7 – Administrative changes

·         Section 4.8 - updated to include hypocalcaemia in connection with severe hypomagnesaemia. Microscopic colitis has also been added.  Addition of AE wording.

·         Section 4.9 - administrative change

·         Section 5.1 - updated with information on Chromogranin A and ECL cell hyperplasia. Text regarding clostridium difficile in hospitalised patients has also been added

·         Section 5.2 – Addition of linearity/non-linearity information and administrative changes.

·         Section 6.5 - updated with an administrative change for clarity of use to explain that the sachet containing the desiccant in the packaging is not to be eaten

·         Section 10 – date of revision

Updated on 16 October 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to drug interactions
  • Change to further information section
  • Change to date of revision
  • Addition of information on reporting a side effect.
  • Improved electronic presentation

Updated on 9 January 2013 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.2

 

Update around non-fixed combination products.

 

Section 4.4

 

Update on overtreatment and non-fixed combination products.

Addition of information on hypomagnesaemia and bone fracture.


Section 4.8

 

Add fracture of hip, wrist and spine as a side effect.

Change frequency of hypomagnesaemia side effect.

 

Section 5.1

 

Administrative changes.

 

Section 5.2

 

Update on Naproxen absorption.

 

Section10

 

Date of revision amended to 12th December 2012.

Updated on 8 January 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to further information section
  • Change to dosage and administration

Updated on 2 October 2012 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4

Addition of Hypomagnesaemia and Bone Fracture.

Section 4.8
 
Addition of bone fracture to side effects for esomeprazole and change frequency of hypomagnesaemia side effect.


Section 10

Date of revision amended to 2nd September 2012

 

Updated on 26 September 2012 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 1 November 2011 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.2
Following text deleted:
because these patients should not receive more than 20 mg esomeprazole per day


Section 4.3
Active peptic ulceration text amended.

Section 4.4
Paragraph 18 text replaced with:
Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter (see section 5.1).

Use in patients with impaired renal function
Not recommended replaced with contraindicated

New paragraph inserted after Hepatic effects:
Hepatorenal syndrome
The use of NSAIDs may be associated with acute renal failure in patients with severe hepato-cirrhosis. These patients frequently also have concomitant coagulopathy related to inadequate synthesis of clotting factors. Antiplatelet effects associated with naproxen could further increase risk of severe bleeding in these patients.

Section 4.5
Amendments to text and percentages in the Clopidogrel paragraph.

Amendments to text and percentages in the Drugs with gastric pH-dependent absorption

Other Information Concerning Drug Interactions
Paragraph 7 and 8 insertion of new text:
Drugs known to induce CYP2C19 or CYP3A4 or both (such as rifampicin and St. John’s Wort) may lead to decreased esomeprazole serum levels by increasing the esomeprazole metabolism.

Omeprazole as well as esomeprazole act as inhibitors of CYP2C19. Omeprazole, given in doses of 40 mg to healthy subjects in a cross-over study, increased Cmax and AUC for cilostazol by 18% and 26% respectively, and one of its active metabolites by 29% and 69% respectively.

Section 5.1
Insertion of text under Other effects related to acid inhibition:
Also chromogranin A (CgA) increases due to decreased gastric acidity.

Decreased gastric acidity due to any means including proton pump inhibitors, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter.

Clinical efficiency and safety
Paragraph updated – text inserted.

Section 5.2
Text change under Special Populations:
Not recommended replaced with contraindicated

Esomeprazole: Text removed:
Therefore, a maximum of 20 mg daily should not be exceeded in patients with severe hepatic impairment.

Section 10
Date amended to 30th September 2011.

Updated on 27 October 2011 PIL

Reasons for updating

  • Change to drug interactions
  • Change to date of revision

Updated on 9 May 2011 PIL

Reasons for updating

  • New PIL for new product

Updated on 6 May 2011 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

None provided